Was the MoonLake Immunotherapeutics (MLTX) CFO share sale under a Rule 10b5-1 plan?

Yes. The filing states the CFO’s sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades, reducing the significance of transaction timing as an indicator of insider sentiment.

MoonLake Immunotherapeutics (MLTX) CFO sells 39,120 shares in open-market trade

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MoonLake Immunotherapeutics’ Chief Financial Officer Matthias Bodenstedt reported an open-market sale of 39,120 Class A ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $22.04 per share, in multiple trades between $19.87 and $23.2049. Following the sale, he directly holds 1,115,435 shares, so the transaction represents a small portion of his stake. The sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance.

Insights

CFO’s 39,120-share sale is modest, pre-planned, and routine.

MoonLake Immunotherapeutics’ CFO, Matthias Bodenstedt, sold 39,120 Class A shares in an open-market transaction at a weighted average of $22.04 on June 22, 2026. The trades occurred over a price range from $19.87 to $23.2049.

After the sale, he still directly owns 1,115,435 shares, so the disposition reflects only a small fraction of his holdings. The filing notes the transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, suggesting the timing was pre-scheduled rather than opportunistic.

Because the sale is relatively small compared with his remaining position and is conducted under a pre-arranged plan, it generally appears as a routine liquidity event rather than a signal of changing views about MoonLake Immunotherapeutics’ prospects based solely on this filing.

Insider Trade Summary 10b5-1

Net Seller: 39,120 shares ($862,205)

Net Sell 1 txn

Insider Bodenstedt Matthias

Role Chief Financial Officer

Sold 39,120 shs ($862K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	39,120	$22.04	$862K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,115,435 shares (Direct, null)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 39,120 shares Average sale price: $22.04 per share Post-transaction holdings: 1,115,435 shares +3 more

6 metrics

Shares sold 39,120 shares Open-market sale on June 22, 2026

Average sale price $22.04 per share Weighted average price for 39,120 shares

Post-transaction holdings 1,115,435 shares Shares directly owned after sale

Low sale price range $19.87 per share Lowest price among multiple trades

High sale price range $23.2049 per share Highest price among multiple trades

Rule 10b5-1 plan adoption date December 10, 2025 Plan governing the June 22, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Class A ordinary shares

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:01 PM Accepted by SEC EDGAR 06/23/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last)

(First)

(Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG

6300

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A ordinary shares, par value $0.0001 per share	06/22/2026		S⁽¹⁾		39,120	D	$22.04⁽²⁾	1,115,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for its CFO?

MoonLake Immunotherapeutics reported that CFO Matthias Bodenstedt sold 39,120 Class A ordinary shares. The open-market sale occurred on June 22, 2026 at a weighted average price of $22.04 per share, across multiple trades within a disclosed price range.

At what prices did the MoonLake Immunotherapeutics (MLTX) CFO sell shares?

The CFO’s 39,120-share sale had a weighted average price of $22.04 per share. Individual trades occurred in a range between $19.87 and $23.2049 per share, according to the Form 4 disclosure and its detailed pricing footnote.

How many MoonLake Immunotherapeutics (MLTX) shares does the CFO still own after the sale?

After the reported transaction, CFO Matthias Bodenstedt directly holds 1,115,435 Class A ordinary shares. This indicates the 39,120 shares sold represent a relatively small portion of his overall reported stake in MoonLake Immunotherapeutics.

What type of transaction code is shown in the MoonLake Immunotherapeutics (MLTX) Form 4?

The Form 4 lists transaction code “S,” which represents a sale in an open-market or private transaction. This confirms the filing reflects a straightforward disposition of common shares rather than an option exercise, gift, or tax-withholding event.